Document is current
Any future updates will be listed below
-
Authors
Goerzen, Dana https://orcid.org/0000-0001-9645-3503
Kim, Mijin https://orcid.org/0000-0002-7781-9466
Schroff, Chanel https://orcid.org/0009-0005-2844-2075
Hoang, Margaret Ngoc
Wollowitz, Jaina Sarris https://orcid.org/0000-0002-5938-4382
Kolb, August https://orcid.org/0009-0002-1173-6147
Walshon, Jordain P.
McCortney, Kathleen https://orcid.org/0000-0001-7085-830X
Horbinski, Craig
Galbraith, Kristyn
Raoof, Sana
Snuderl, Matija
Ordureau, Alban https://orcid.org/0000-0002-4924-8520
Heller, Daniel A. https://orcid.org/0000-0002-6866-0000
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 22 October 2025
First Online: 24 December 2025
Competing interests
: D.A.H. is a co-founder, board member and officer with equity interest in Nine Diagnostics Inc., a co-founder with equity interest and intellectual property interests in Selectin Therapeutics Inc., and a co-founder with equity in Lime Therapeutics Inc., a member of the scientific advisory boards of Concarlo Therapeutics Inc., Celine Therapeutics Inc., Nanorobotics Inc., and Mediphage Bioceuticals Inc., and a consultant for Metis Therapeutics Inc. M.K. is a co-founder and officer with equity interest in Nine Diagnostics. S.R. is a consultant to Grail, Exact Sciences, C the Signs, and the American Cancer Society. M.S. is a scientific advisor and shareholder of Heidelberg Epignostix and Halo Dx, a scientific advisor of Arima Genomics and InnoSIGN, has consulted for Servier Pharmaceuticals, and has received research funding from Lilly USA. The other authors declare no competing interests.
